Indaptus Therapeutics Future Growth

Future criteria checks 0/6

Indaptus Therapeutics is forecast to grow earnings and revenue by 44.8% and 69.6% per annum respectively while EPS is expected to grow by 50.5% per annum.

Key information

44.8%

Earnings growth rate

50.5%

EPS growth rate

Biotechs earnings growth	26.8%
Revenue growth rate	69.6%
Future return on equity	n/a
Analyst coverage	Low
Last updated	12 Nov 2024

Recent future growth updates

Recent updates

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth?

Mar 27

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Deliver On Growth Plans?

Aug 15

Indaptus Therapeutics GAAP EPS of -$0.46 beats by $0.45

Aug 08

Indaptus Therapeutics: Advancing Decoy Technology To Address Cancer And Viral Indications

Sep 29

Earnings and Revenue Growth Forecasts

NasdaqCM:INDP - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	N/A	-23	N/A	N/A	1
12/31/2026	N/A	-22	N/A	N/A	1
12/31/2025	N/A	-21	N/A	N/A	2
12/31/2024	N/A	-15	N/A	N/A	2
9/30/2024	N/A	-15	-12	-12	N/A
6/30/2024	N/A	-16	-13	-13	N/A
3/31/2024	N/A	-15	-12	-12	N/A
12/31/2023	N/A	-15	-13	-13	N/A
9/30/2023	N/A	-15	-13	-13	N/A
6/30/2023	N/A	-15	-14	-14	N/A
3/31/2023	N/A	-15	-15	-15	N/A
12/31/2022	N/A	-14	-13	-13	N/A
9/30/2022	N/A	-14	-14	-14	N/A
6/30/2022	N/A	-14	-15	-15	N/A
3/31/2022	N/A	-10	-14	-14	N/A
12/31/2021	N/A	-8	-11	-11	N/A
9/30/2021	N/A	-5	-9	-9	N/A
6/30/2021	N/A	-3	-4	-4	N/A
3/31/2021	N/A	-4	-4	-4	N/A
12/31/2020	N/A	-4	-3	-3	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: INDP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: INDP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: INDP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: INDP is forecast to have no revenue next year.

High Growth Revenue: INDP is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if INDP's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/13 07:37
End of Day Share Price	2025/01/10 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Indaptus Therapeutics, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Raghuram Selvaraju	H.C. Wainwright & Co.
Jason McCarthy	Maxim Group

Indaptus Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target increased by 15% to US$15.00

Price target decreased to US$11.00

Recent updates

New major risk - Market cap size

Insufficient new directors

Indaptus Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.134995 million.

New major risk - Financial position

Indaptus Therapeutics, Inc. Presents Clinical Data on Decoy20 at SITC 2024 Annual Meeting

Indaptus Therapeutics, Inc. Provides Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data

New minor risk - Shareholder dilution

Indaptus Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.000003 million.

Indaptus Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $0.3 million.

Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20

Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth?

New major risk - Financial position

New minor risk - Share price stability

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial

Indaptus Therapeutics, Inc. Announces Interim Data from the First Cohort of Four Patients in the Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20

Indaptus Therapeutics, Inc. Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Deliver On Growth Plans?

Indaptus Therapeutics, Inc. Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

Indaptus Therapeutics, Inc. Appoints Roger Waltzman as Its Chief Medical Officer, Effective August 7, 2023

Price target increased by 15% to US$15.00

Indaptus Therapeutics, Inc. Names Robert Martell, M.D., Ph.D. to Its Board of Directors

Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Price target decreased to US$11.00

High number of new and inexperienced directors

Indaptus Therapeutics GAAP EPS of -$0.46 beats by $0.45

Indaptus Therapeutics, Inc., Annual General Meeting, Sep 29, 2022

CEO & Director recently bought US$52k worth of stock

Indaptus Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors

High number of new and inexperienced directors

High number of new and inexperienced directors

CEO & Director recently bought US$65k worth of stock

Insider recently bought US$691k worth of stock

Indaptus Therapeutics: Advancing Decoy Technology To Address Cancer And Viral Indications

CEO & Director recently bought US$84k worth of stock

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources